Cases & Deals

  • Home
  • Practices
  • Opus Bio and Juno Therapeutics sign license agreement relating to CD-22 targeted cancer therapy

Share

Opus Bio and Juno Therapeutics sign license agreement relating to CD-22 targeted cancer therapy

December 2014

Client(s) Opus Bio, Inc.

Jones Day advised Opus Bio, Inc., a diversified biologics company, in connection with an exclusive patent licensing agreement with Juno Therapeutics, Inc., a U.S. biopharmaceutical company, covering a CAR T-cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas. The CD22-targeted CAR T-cell product candidate was developed by the National Cancer Institute (NCI) under cooperative research and development agreement (CRADA) with Opus Bio, Inc. The NCI has begun enrollment in a Phase I trial evaluating pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL).

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.